A special feature covering the latest in pharma innovation, manufacturing and development.
An Endpoints Day focused on clinical trials, featuring a panel session hosted by an Endpoints journalist and more. What are the latest trends in clinical trials? What regulatory curves are making the biggest waves? We’ll also take a look at how expectations from the industry and beyond are shifting the trial strategies of the future.
An Endpoints Day focused on drug discovery, featuring a panel session hosted by an Endpoints journalist with more sessions to be announced. This event will focus on research pipelines, emerging drug targets and the inflection point of research to development.
Who are the women leading and influencing biopharma? Each year we seek out the up-and-comers moving the industry forward. Our in-depth profiles establish their stories into the fabric of an industry that isn’t changing fast enough to keep up with gender diversity.
The pandemic spotlight on the world of manufacturing shifted the sector into a radical reality. Now that the world has moved forward — how has the new landscape affected the industry? From supply chain drain to capital expenditure hurdles, how exactly do we scale up and out? Join Endpoints for our first manufacturing day to find out what the experts are saying about the unique environment we are facing today.
An Endpoints Day focused on drug commercialization, featuring a panel hosted by an Endpoints journalist with more sessions to be announced. This event will focus on trends in drug launches, marketing and sales.
What’s in store for the future of R&D in Europe? We’re charting the waters ahead this year and beyond — covering drug development, financing trends, regulatory issues and more on topics central to the biopharma industry. Our two-day hybrid event will be held live at the Financial Times headquarters in London — join us in person or tune in virtually. Access sessions covering the latest on the VC landscape, dealmaking in Europe and one-on-one chats featuring industry leader interviews by our journalists.